Emergency Use Listing For Covaxin

Emergency Use Listing For Covaxin To Be Considered On October 26

India might have to wait a bit for WHO (World Health Organization) to approve the emergency use of Bharat Biotech’s indigenously produced Covaxin. On 17th October, Soumya Swaminathan, Chief Scientist of WHO mentioned on Twitter that the technical advisory team assessing the vaccine will hold a meeting the next Tuesday to talk about the EUL (Emergency Use Listing) for Bharat Biotech’s Covaxin. She additionally said that WHO is working in partnership with Bharat Biotech, Hyderabad for completing the formalities.

Dr. Soumya Swaminathan tweeted that the technical advisory team will discuss Covaxin’s EUL on October 26th. Their aim is to increase access globally and have a wide range of vaccines authorized for emergency use.

Covaxin Gets Nod For EUA For Use In Children- Read More At Biotecnika

Upon the request by WHO, Bharat Biotech presented further

data on Covaxin by last Month. WHO extended providing the EUL for Bharat Biotech’s Covaxin by one week on October 5th. With this latest advancement, India can now anticipate the approval of emergency use for Covaxin, Bharat Biotech’s vaccine for COVID-19, by the end of October.

WHO in another tweet informed that the EUL process carried out by the technical advisory team and WHO is focussed on ascertaining if the produced vaccine is effective, safe, and quality-assured.

Bharat Biotech’s indigenously manufactured Covaxin is one among the six vaccines that have been approved by drug regulators in India for emergency use. Covaxin is being employed throughout the country for the anti-COVID-19 vaccination program together with Sputnik V and Covishield. Bharat Biotech developed the COVID-19 vaccine in partnership with NIV (National Institute of Virology) and ICMR (Indian Council of Medical Research).


Emergency Use Listing For Covaxin